Covered recipient · General Payments record
REBECCA ANN LOWE
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2023–2024
$843.01
- Reported across 40 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $282.93 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Sumitomo Pharma America, Inc. | $50.44 | 3 |
| PFIZER INC. | $45.50 | 2 |
| Novo Nordisk AS | $42.28 | 2 |
| Amgen Inc. | $37.37 | 2 |
| Lilly USA, LLC | $36.08 | 2 |
| GlaxoSmithKline, LLC. | $20.48 | 1 |
| Phathom Pharmaceuticals, Inc. | $19.22 | 1 |
| ANI Pharmaceuticals, Inc. | $16.15 | 1 |
| Janssen Pharmaceuticals, Inc | $15.41 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $15.53 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117314308 | CMS |
| Amgen Inc. | $21.84 | 11/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117314310 | CMS |
| ANI Pharmaceuticals, Inc. | $16.15 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1091136901 | CMS |
| GlaxoSmithKline, LLC. | $20.48 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116687263 | CMS |
| Janssen Pharmaceuticals, Inc | $15.41 | 08/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078043904 | CMS |
| Lilly USA, LLC | $16.56 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135900158 | CMS |
| Lilly USA, LLC | $19.52 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135918672 | CMS |
| Novo Nordisk Inc | $21.12 | 06/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100540876 | CMS |
| Novo Nordisk Inc | $21.16 | 07/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100249678 | CMS |
| PFIZER INC. | $21.43 | 05/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131656010 | CMS |
| PFIZER INC. | $24.07 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131656014 | CMS |
| Phathom Pharmaceuticals, Inc. | $19.22 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151184528 | CMS |
| Sumitomo Pharma America, Inc. | $17.98 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148977017 | CMS |
| Sumitomo Pharma America, Inc. | $16.13 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148977019 | CMS |
| Sumitomo Pharma America, Inc. | $16.33 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148977021 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.